OBJECTIVE: To estimate the incremental delivery cost of human papillomavirus (HPV) vaccination of young adolescent girls in Peru, Uganda and Viet Nam. METHODS: Data were collected from a sample of facilities that participated in five demonstration projects for hpv vaccine delivery: school-based delivery was used in Peru, Uganda and Viet Nam; health-centre-based delivery was also used in Viet Nam; and integrated delivery, which involved existing health services, was also used in Uganda. Microcosting methods were used to guide data collection on the use of resources (i.e. staff, supplies and equipment) and data were obtained from government, demonstration project and health centre administrative records. Delivery costs were expressed in 2009 United States dollars (US$). Exclusively project-related expenses and the cost of the vaccine were excluded. FINDINGS: The economic delivery cost per vaccine dose ranged from US$ 1.44 for integrated outreach in Uganda to US$ 3.88 for school-based delivery in Peru. In Viet Nam, the lowest cost per dose was US$ 1.92 for health-centre-based delivery. Cost profiles revealed that, in general, the largest contributing factors were project start-up costs and recurrent personnel costs. The delivery cost of HPV vaccine was higher than published costs for traditional vaccines recommended by the Expanded Programme on Immunization (EPI). CONCLUSION: The cost of delivering HPV vaccine to young adolescent girls in Peru, Uganda and Viet Nam was higher than that for vaccines currently in the EPI schedule. The cost per vaccine dose was lower when delivery was integrated into existing health services.
OBJECTIVE: To estimate the incremental delivery cost of human papillomavirus (HPV) vaccination of young adolescent girls in Peru, Uganda and Viet Nam. METHODS: Data were collected from a sample of facilities that participated in five demonstration projects for hpv vaccine delivery: school-based delivery was used in Peru, Uganda and Viet Nam; health-centre-based delivery was also used in Viet Nam; and integrated delivery, which involved existing health services, was also used in Uganda. Microcosting methods were used to guide data collection on the use of resources (i.e. staff, supplies and equipment) and data were obtained from government, demonstration project and health centre administrative records. Delivery costs were expressed in 2009 United States dollars (US$). Exclusively project-related expenses and the cost of the vaccine were excluded. FINDINGS: The economic delivery cost per vaccine dose ranged from US$ 1.44 for integrated outreach in Uganda to US$ 3.88 for school-based delivery in Peru. In Viet Nam, the lowest cost per dose was US$ 1.92 for health-centre-based delivery. Cost profiles revealed that, in general, the largest contributing factors were project start-up costs and recurrent personnel costs. The delivery cost of HPV vaccine was higher than published costs for traditional vaccines recommended by the Expanded Programme on Immunization (EPI). CONCLUSION: The cost of delivering HPV vaccine to young adolescent girls in Peru, Uganda and Viet Nam was higher than that for vaccines currently in the EPI schedule. The cost per vaccine dose was lower when delivery was integrated into existing health services.
Authors: Gustavo H Dayan; Lisa Cairns; Nalinee Sangrujee; Anne Mtonga; Van Nguyen; Peter Strebel Journal: Vaccine Date: 2004-01-02 Impact factor: 3.641
Authors: Mary Penny; Rosario Bartolini; N Rocio Mosqueira; D Scott LaMontagne; Maria Ana Mendoza; Irma Ramos; Jennifer L Winkler; Jose Villafana; Amynah Janmohamed; Aisha O Jumaan Journal: Vaccine Date: 2011-05-24 Impact factor: 3.641
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: D Scott LaMontagne; Sandhya Barge; Nga Thi Le; Emmanuel Mugisha; Mary E Penny; Sanjay Gandhi; Amynah Janmohamed; Edward Kumakech; N Rocio Mosqueira; Nghi Quy Nguyen; Proma Paul; Yuxiao Tang; Tran Hung Minh; Bella Patel Uttekar; Aisha O Jumaan Journal: Bull World Health Organ Date: 2011-09-01 Impact factor: 9.408
Authors: Ulla K Griffiths; Lara J Wolfson; Arshad Quddus; Mohammed Younus; Rehan A Hafiz Journal: Bull World Health Organ Date: 2004-09 Impact factor: 9.408
Authors: Jane K Cover; Nguyen Quy Nghi; D Scott LaMontagne; Dang Thi Thanh Huyen; Nguyen Tran Hien; Le Thi Nga Journal: BMC Public Health Date: 2012-08-09 Impact factor: 3.295
Authors: J Obel; J McKenzie; L E Buenconsejo-Lum; A M Durand; A Ekeroma; Y Souares; D Hoy; W Baravilala; S M Garland; S K Kjaer; A Roth Journal: Asian Pac J Cancer Prev Date: 2015
Authors: Emmanuel Mugisha; D Scott LaMontagne; Anne R Katahoire; Daniel Murokora; Edward Kumakech; Rachel Seruyange; Vivien Davis Tsu Journal: Afr Health Sci Date: 2015-03 Impact factor: 0.927
Authors: Joël Ladner; Marie-Hélène Besson; Mariana Rodrigues; Etienne Audureau; Joseph Saba Journal: BMC Public Health Date: 2014-06-30 Impact factor: 3.295
Authors: Hoang Van Minh; Kim Bao Giang; Luu Ngoc Hoat; Le Hong Chung; Tran Thi Giang Huong; Nguyen Thi Kim Phuong; Nicole B Valentine Journal: Glob Health Action Date: 2016-02-04 Impact factor: 2.640
Authors: Moses Muia Masika; Javier Gordon Ogembo; Sophie Vusha Chabeda; Richard G Wamai; Nelly Mugo Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240
Authors: D Scott LaMontagne; Nguyen Quy Nghi; Le Thi Nga; Amynah Janmohamed; Dang Thi Thanh Huyen; Nguyen Tran Hien; Vivien Davis Tsu Journal: BMC Public Health Date: 2014-06-05 Impact factor: 3.295